Board

Dario Neri, Ph.D

Chief Executive Officer  & Chief Scientific Officer
Co-founder

Dario Neri is Co-founder, CEO, CSO and President of the Scientific Advisory Board of Philogen. He graduated in Chemistry at the Scuola Normale Superiore in Pisa and obtained his Ph.D. in Chemistry from ETH Zurich, under the supervision of Prof. Kurt Wüthrich, winner of the Nobel Prize for Chemistry in 2002. For his dissertation, he was awarded the Silver Medal of ETH. After a 5 years post-doctoral research position in the lab of 2018 Chemistry Nobel Price Winner Sir Gregory Winter at the Cambridge Centre of Protein Engineering in Cambridge, UK, he returned to ETH Zurich in 1996 as Assistant Professor in Molecular Structure Biology. From 1999 he has been a Professor of Biomacromolecules in the department of Chemistry and Applied Biosciences at ETH Zurich, before he permanently joined Philogen in 2020.

Prof. Neri is recipient of numerous awards, including the ISOBM Abbott Prize 2000, of the Amgen-Dompe’ Biotec Award 2000, the Prous Award 2006 of the European Federation of Medicinal Chemistry and the Phoenix Prize 2014 and is author of more than 400 publications in international scientific journals.

Duccio Neri

Executive Chairman
Co-founder

Duccio Neri is Co-founder and Chairman of Philogen. He graduated in Business Administration and Economics at the Bocconi University in Milan, specializing in Corporate Finance. Dr. Neri has a special expertise in Financial Consulting, Tax and Audit Advice and Business Administration and is a Partner of the “Studio Neri – Tanini”. He was a representative of the Italian Government in the Board of the University of Siena and an auditor of the Cassa di Risparmio di San Miniato (CRSM) S.p.A., MPS Banca Verde S.p.A., MPS Fiduciaria S.p.A., MPS Professional S.p.A., and of several other firms.

Giovanni Neri, Ph.D.

Head of Licensing & IP
Co-founder

Giovanni Neri is Co-founder and Director of IP & Licensing at Philogen S.p.A. Dr. Neri graduated in Biology at the University of Siena where he also received his doctorate in Biotechnology. He later specialized in antibody therapeutics in clinical oncology at the Royal Postgraduate Medical School at the Hammersmith Hospital, London from 1993 to 1995. At Philogen, he is responsible for developing the company’s patent portfolio and is involved in the conclusion of all the major contractual agreements.

Sergio Dompé

Sergio Gianfranco Luigi Maria Dompé obtained three honorary degrees (pharmaceutical biotechnology from the University of Bologna in 1996, medical biotechnology from the University of L’Aquila in 2005 and pharmacy from the University of Urbino in 2010), as a result of his commitment to the pharmaceutical industry. In 1976, he started working for Dompé Farmaceutici S.p.A., founded by his father in 1940, and right from the start, brought many changes to the company’s strategy. He was among the first entrepreneurs in the industry to believe strongly in the opportunities offered by biotechnology for the development of new drugs. On the basis of this intuition, he established partnerships with global pharmaceutical companies to provide patients with new therapeutic benefits. Sergio Dompé holds the office of Chairman of Dompé Farmaceutici S.p.A., holding company of Dompé Group, which operates through three different companies: Dompé, Amgen Dompé and Biogen Dompé. It employs 800 persons globally and registered a turnover of 529.4 million Euros in 2010. From 1998 to 2004 Sergio Dompé was Chairman of Assobiotech for three consecutive terms. In June 2005 he was appointed President of Farmindustria, the Italian Pharmaceutical Companies’ Association and member of the Confindustria Council. Since January 2006 he has been Chairman of the Assessment Committee of the CNR (Italian Research Council). Since July 2007 he has been member of the Council of the Italian Institute of Technology foundation.

Nathalie Dompé

Nathalie Dompé is Vice President for Business Development at Dompé Pharmaceuticals and is in charge of oversight, market development and strategic approval of all new programs launched by Dompé in the United States. Nathalie is concurrently CEO of Dompé Holdings, a diversified holding company in Europe with business interests in pharmaceuticals, agriculture and hi-tech. Nathalie is Board Director of several companies including Movendo, Bonifiche Ferraresi, Philogen and Dompé Pharmaceuticals. Born in Milan, Italy, in 1986, Nathalie graduated with Honors in Business Administration from Bocconi University in Milan.

Marta Bavasso

Indipendent Director

Marta Bavasso graduated with a degree in Law from the University of Florence in 1993 including LLM education in EU Law and Institutions, EU Competition Law, International Commercial Law from the University College London. Qualified to practice as an attorney since 1997, she has worked for important national and international law firms, including MacKenzie Mills (currently Withersworldwide), Ernst &Young and Chiomenti for which she has followed relevant M&A transactions, joint ventures, private equity, fund structuring, IPOs, ICT practices of various nature, in different sectors. From 2000 to 2005 she worked as in-house legal counsel in the M&A department of Enel S.p.A. and, subsequently, in the start-up of H3G S.p.A. (later Wind Tre S.p.A.) – Group Hutchinson Whampoa Limited (HWL). In 2019 she launched, with other funding partners, a new law firm IPG Lex (currently IPG Lex&Tax-Studio Legale Tributario), as partner for corporate-m&a-private equity and TMT. Since February 2022 she is funding partner of the law firm Gambino-Scanzano-Pesce-Bavasso, with offices in Rome/Milan, and responsible for corporate-m&a-private equity and TMT. She is currently board member of Ericsson Telecomunicazioni S.p.A and independent board member of Generalfinance S.p.A. (GF – BIT).

.

Roberto Ferraresi

Indipendent Director

Roberto Ferraresi graduated with honors in Business Administration at Bocconi University in Milan. Mr. Ferraresi started his career at UBS Investment bank in London in 1998. He then joined PAI partners in 2004 where, as a partner, he was actively involved in investment deals of more than €700 million. Mr. Ferraresi became board member of both private and listed companies. Since January 2018 he is founder and CEO of The Equity Club , a private equity initiative in the form of club deal, promoted together with Mediobanca and counting more than 90 investors among the most prominent families in Italy.

Maria Giovanna Calloni

Born in Dairago (MI) in 1964, she graduated in Economia Aziendale summa cum laude from Università Commerciale Luigi Bocconi, Milan in 1987. From 1987 to 1990, Ms. Calloni worked as a business analyst at Memorex Telex in Milan, London and New York. In 1992, she obtained her M.B.A. with honors at the Leonard Stern School of Business, New York University. Upon graduation, she was hired by the investment bank Merrill Lynch in New York where she initially worked as Associate in Investment Banking (1992-1995) and subsequently as Director in Equity Capital Markets (1995-2002). Since her return to Italy, Ms. Calloni has been carrying out investment activities in private companies operating in renewables, fintech and tech sectors. She also actively provides financial advisory services – with a focus on capital raising and M&A processes – to portfolio companies. Currently, Ms. Calloni also serves on the board of directors of Industrie De Nora, which operates in the field of sustainable technologies for electrochemical industrial processes and water treatment, and Pininfarina, which is active in the automotive and industrial design sector. In the recent past, she served as an independent member of the Board of Directors of Credito Valtellinese (2019-2021) and CAD IT (2019-2021) and as executive board member of Deus Technology (2018-2019).

Guido Guidi, MD

Guido Guidi has 35 years of experience in the pharmaceutical industry. He received his medical training at the University of Milan, where he obtained his MD in 1979. He continued his specialized training in Immunology and Allergology, as well as in Rheumatology in Milan until 1989. In parallel, he served as a medical advisor for Smith Kline and Roussel UCLAF and was medical director at Sharper Italia (Roussel UCLAF Group) from 1986 to 1989.

Dr. Guidi was previously Head of Pharma Europe and Head of Oncology Europe at Novartis, where he was responsible for bringing various drugs from clinical development to market including Cosentryx, Entresto, Lucentis, Gilenya, Xolair, Ultibro, Sandostatin, Femara, Glivec and Jiakavi. While at Novartis, Guido originated and chaired the first edition of Bioupper, the Novartis accelerator for early-stage projects in Italy. He was also Chairman of the Novartis European Executive Committee and a member of the Innovation Management Board responsible for the Pharma division’s R&D program. He has also held different medical positions within Novartis, Sandoz, Roussel-UCLAF and GSK. Guido is currently Chairman, Co-Founder and Managing Partner of the technology transfer company AurorA-TT.

Leopoldo Zambeletti

Mr. Zambeletti is an Independent Strategic and Financial Advisor in the Healthcare sector. During his 25-year career as an investment banker, Mr Zambeletti led the EMEA Healthcare Investment Banking team at JP Morgan for eight years before taking up the same position at Credit Suisse for a further five years. He is a Non-Executive Director of Faron (AIM), Nogra Pharma, The Meatless Farm, Buccuico Ltd., Afimmune and DS Biopharma. Mr Zambeletti started his career at KPMG as an auditor and received a BA in Business from Bocconi University in Milan, Italy.